Scores on the QLS and the SIP-modified version improved uniformly in the three groups after the switch. There were no significant differences between the three novel antipsychotics. In another comparative open-label study, Ho et al28 did not find differential effects of risperidone and olanzapine on patients’ quality of life. They included 42 schizophrenic (DSM-IV criteria42) inpatients; 21 of them were started on risperidone (mean baseline dose 5.7 mg/day) and the remaining 21 on olanzapine (mean baseline dose 14.4 mg/day) based on Inhibitors,research,lifescience,medical the treating psychiatrist’s decision.

Quality of life was assessed using the Psychiatric Status You Currently Have-Baseline version (PSYCH-BASE)50 and its longitudinal follow-up version, the PSYCH-UP. The PSYCH-BASE is a structured interview with eight quality of life indices: occupational impairment, financial Inhibitors,research,lifescience,medical dependence, impairment in performance of household duties, relationship impairment with family members and with friends, enjoyment of recreational activities, satisfaction, and overall psychosocial functioning. A total of 26 patients

(13 in each group) completed the 6-month followup interview. At follow-up there were no statistically differential effects between the two treatments on the eight quality of life indices. Significant Inhibitors,research,lifescience,medical improvements at time of follow-up were reported on overall psychosocial functioning in the risperidone group and on impairment in performance of household Brefeldin A duties in the olanzapine group. Tran et al29 compared olanzapine with risperidone in an international, 28-week, double-blind, randomized study. Three hundred and thirty Inhibitors,research,lifescience,medical nine (olanzapine n=172, risperidone n=167) schizophrenic, schizophreniform, or schizoaffective patients

(DSM-IV criteria42) were assessed using the QLS.35 In both treatment groups, statistically significant improvements were observed on the QLS total score and on the four subscales from baseline to end point. Olanzapine demonstrated significant greater improvement in QLS interpersonal relations subscale scores than risperidone. Risperidone Bobes et al31 studied Inhibitors,research,lifescience,medical the effect of risperidone monotherapy maintenance treatment on the quality of life of 318 schizophrenic outpatients (The ICD-10 Classification of Megestrol Acetate Mental and Behavioral Disorders, Clinical descriptions and diagnostic guidelines, ICD-1051 criteria) who had been previously treated with other neuroleptics. Quality of life was assessed employing the SF-36.48 At month 8, significant improvement was observed in all SF-36 scale scores and in the summary measures. The greatest improvement was observed in the role emotional scale, followed by the role physical and the social functioning. Hertling et al30 compared the impact of risperidone and flupenthixol upon the quality of life of schizophrenic inpatients and outpatients with mainly negative symptoms.